TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024. In the quarter to June 2026, revenue grew 70.3%, EPS fell 73.7%, free cash flow grew 427.1% and total debt rose 204.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

53.97 2.03 −3.63%
Market cap
$8.6B
P/E
17.8×
Fwd P/E
29.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

111.96% 102.75% 112.60% 100.28%
Piotroski F-Score
4 4 4 5
ROA
55.55% 54.50% 42.27% 37.70%
ROIC
8.91% 10.25% 11.48% 10.69%
Return on Tangible Assets
101.02% 93.75% 51.33% 50.33%
Average Days of Receivables
182.11 181.01 204.32 183.32
Free Cash Flow per Share
(0.48) (0.17) (0.10) 0.12
Free Cash Flow
(70.24) (24.99) (14.19) 17.39
Other line items

Show all line items

Columns are period end dates